6th Oct 2016 OxStem Ltd wins best start-up biotech company award at the Oxfordshire Bioscience Network (OBN) 2016 awards ceremony.
4th Oct 2016 Welcome to our new group members Sophie, Abi, Katie and Sean.
28th Sep 2016 Steve's h-index (Web of Science) has
increased to 59.
5th Aug 2016 Two new subsidiaries of OxStem Ltd have been launched. OxStem Neuro, co-founded with Prof. Francis Szele (Physiology, Anatomy and Genetics), aims to identify drugs that will stimulate de novo neuron production from neural stem cells that will compensate for disease pathology in neurodegenerative diseases, stroke and traumatic brain injury. OxStem Ocular, co-founded with Prof. Robert MacLaren (Nuffield Laboratory of Ophthalmology), aims to identify drugs that will stimulate precursor cells within the retina of patients for retinal repair and restoration of vision. Further information can be found on the OxStem website website.
17th Jun 2016 Our paper on the asymmetric synthesis of
(+)-preussin B and its analogues has been featured on the cover of J. Org. Chem. [View Journal Page]
17th Jun 2016 Congratulations to Dr Marta Brambilla on the completion of her D.Phil.
13th May 2016 Download an updated copy of our Drug Discovery Glossary (version 2.0) here.
11th May 2016 OxStem's record fundraising round is featured in Financial Times. The story highlights the importance of unlocking the potential of research from UK universities to translational medicine; OxStem will address a number of therapeutic areas in regenerative medicine including cancer, heart failure and neurodegenerative diseases. FT subscribers can read the article here.
10th May 2016 OxStem, an Oxford spin-out founded by Prof. Steve Davies, Prof. Angela Russell (Department of Chemistry) and Prof. Dame Kay Davies (Department of Physiology, Anatomy and Genetics), has raised a record £16.9M to develop small molecule drug candidates to treat age-related conditions including cancer, neurodegenerative diseases and heart failure. The company has formed strategic partnerships with Human Longevity Inc. and CEO Dr J Craig Venter together with Mr Bob Duggan and Dr. Mahkam Zanganeh (former CEO & Chairman and Chief Operating Officer respectively) of Pharmacyclics that was sold last year to Abbvie for US$21 billion. Other individual investors, together with Oxford Science Innovation, will enable OxStem to fund the development of a series of daughter companies - each with a focus on a different large unmet therapeutic need. The majority of the £16.9M is expected to be used to fund joint projects between the Department of Pharmacology, the Department of Chemistry and other Departments across Oxford over the next three years.
[View Press Release]
15th Apr 2016 Our paper on the asymmetric synthesis of
(+)-preussin B and its analogues has been selected as a Featured Article in J. Org. Chem. [View Journal Page]
24th Mar 2016 Congratulations to Alex White on the completion of his MSc (Res).
9th Mar 2016 Steve's h-index (Web of Science) has
increased to 58.